Anti-cancer therapy-induced metabolic syndrome.
Vnitr Lek
; 67(6): 334-338, 2021.
Article
in En
| MEDLINE
| ID: mdl-35459375
ABSTRACT
The increasing number of long-term survivors that underwent the anti-cancer therapy faces the late treatment-related adverse effects and the increased risk of developing metabolic syndrome. This article defines the pathophysiology that underlies development of anti-cancer therapy-related metabolic syndrome and outlines the possibility of optimisation of comprehensive care focusing on prevention. Considering the preventability of metabolic syndrome, effective screening and follow-up appropriate for patients at increased risk of related adverse events should be established. Subsequently, early initiation of therapy targeting the hallmarks of metabolic syndrome may ease its manifestation in long-term perspective.
Key words
Search on Google
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Metabolic Syndrome
/
Neoplasms
Limits:
Humans
Language:
En
Journal:
Vnitr Lek
Year:
2021
Document type:
Article